Pooled data from two major trials shows semaglutide reduced serious cardiovascular events by 26% in diabetes patients with established heart disease, with signs the benefit may extend to lower-risk patients too.
HR 0.7426% reduction in major adverse cardiovascular events with semaglutide vs placebo in patients with established cardiovascular disease using stricter REWIND criteria
What the researchers found
Semaglutide reduced MACE by 26% (HR 0.74) in patients with established CVD using REWIND criteria, with a non-significant 16% reduction in the risk factor subgroup (p-interaction=0.60).
Why it matters
This suggests semaglutide's heart protection is not limited to the highest-risk patients, potentially broadening who should receive it.
The numbers in context
6,480 patients; established CVD HR 0.74 (0.59-0.92); risk factor HR 0.84 (0.55-1.28); p-interaction 0.60; 66.5% established CVD by REWIND criteria
How the study worked
Post hoc pooled analysis of SUSTAIN 6 and PIONEER 6 trials (n=6,480). Re-categorized patients using REWIND cardiovascular disease criteria. Compared MACE outcomes.
Who was studied
6,480 patients with type 2 diabetes pooled from SUSTAIN 6 and PIONEER 6 trials
What this study cannot tell us
Post hoc analysis, not a prospective trial. Re-categorization changed group sizes. The risk factor subgroup result was not statistically significant.
How to read the evidence
This is a post hoc pooled analysis of two large randomized trials — strong underlying data but exploratory in nature. The established CVD result is statistically significant, but the risk factor subgroup result is not. Prospective confirmation would be needed.
When this study was published
Published in 2021. The cardiovascular benefits of GLP-1 agonists have since been further established through additional trials and meta-analyses. This analysis remains relevant to ongoing discussions about which patients benefit most.
The bigger picture
GLP-1 agonists have proven cardiovascular benefits, but clinical guidelines vary on which patients should receive them specifically for heart protection. This analysis supports the idea that semaglutide's benefits aren't limited to patients who've already had a heart attack or stroke — they may extend to those with risk factors alone. If confirmed in prospective studies, this could significantly expand guideline recommendations for who should receive semaglutide for cardiovascular protection.
Questions still open
- Would a prospective trial in lower-risk diabetes patients confirm the cardiovascular benefit trend seen here?
- How do semaglutide's cardiovascular benefits compare to dulaglutide's across the same risk categories?
- Should current guidelines be updated to recommend GLP-1 agonists for cardiovascular protection in diabetes patients without established heart disease?
Common questions
What does MACE mean and why does it matter?
Why did they reanalyze the data using different criteria?
Read the original research
Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
Diabetes, obesity & metabolism, 23(7), 1677-1680
Citation
Verma, Subodh; Fainberg, Udi; Husain, Mansoor; Rasmussen, Søren; Rydén, Lars; Ripa, Maria Sejersten; Buse, John B. (2021). Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.. Diabetes, obesity & metabolism, 23(7), 1677-1680. https://doi.org/10.1111/dom.14360